Table 1.
Clinicopathological features of 22 bladder cancer patients examined as test cases
| ID | Sex | Age | Stage | Grade | Response | Post treatment |
|---|---|---|---|---|---|---|
| BC01026 | M | 58 | T3b | G3 | Responder (CR) | Radiation |
| BC01028 | M | 69 | T3a | G2 | Responder (CR) | Cystectomy |
| BC01029 | F | 67 | T3a | G3 | Responder | TUR‐Bt |
| BC01031 | M | 74 | T3b | G2 | Responder | Cystectomy |
| BC01033 | F | 68 | T3b | G2 | Responder | Cystectony |
| BC01011 | M | 64 | T3b | G2 > G3 | Non‐responder | Cystectomy |
| BC01027 | M | 72 | T2b | G2 | Non‐responder | Cystectomy |
| BC01032 | F | 64 | T3b | G3 >> G2 | Non‐responder | Radiation |
| BC05002 | M | 60 | T3b | G2 | Non‐responder | Radiation |
| BC01034 | M | 60 | T2b | G2 | Responder (CR) | Cystectomy |
| BC01035 | M | 62 | T3b | G1 > G2 | Responder | Cystectomy |
| BC01036 | M | 73 | T3b | G3 | Non‐responder | MVACx4 |
| BC01039 | M | 75 | T3b | G1 = G2 | Non‐responder | Radiation |
| BC01041 | M | 59 | T2b | G1 = G2 | Responder | Cystectomy |
| BC01043 | M | 69 | T3b | G2 | Non‐responder | Radiaton |
| BC01044 | F | 68 | T3b | G3 | Responder | Radiaton |
| BC01045 | M | 73 | T3a | G3 > G2 | Non‐responder | MVACx3 |
| BC01046 | M | 60 | T3b | G2 | Responder | MVACx3, Cystectomy |
| BC01047 | F | 65 | T3b | G2 > G3 | Non‐responder | MVACx3, Cystectomy |
| BC01050 | F | 65 | T3b | G2 | Non‐responder | MVACx3, Cystectomy |
| BC01055 | M | 74 | T3b | G2 > G1 | Non‐responder | MVACx3, Radiation |
| BC04004 | M | 69 | T2 | G2 | Non‐responder | Cystectomy |
CR, complete response(pT0); F, female; M, male; Non‐responder, patient who could not archive downstaging (>pT1 or >T1) after two courses of treatment; Response, response to neoadjuvant M‐VAC treatment; Responder, patient who archived downstaging (≤pT1 or ≤T1) after two courses of treatment; Test, samples used for test cases; TUR‐Bt, transurethral resection of the bladder tumor.